Annual report pursuant to Section 13 and 15(d)

INCOME TAXES (Details)

v3.22.0.1
INCOME TAXES (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Deferred tax assets      
Net operating loss carryforwards $ 229,364 $ 240,767  
Orphan drug and research and development credits 66,616 64,252  
Deferred compensation 8,819 7,760  
Lease liabilities 2,564 4,399  
Capitalized Inventory 47 34  
Deferred revenue 16,297 1,405  
Other, net 1,626 1,765  
Deferred tax liabilities      
Operating lease right-of-use asset (2,335) (4,084)  
Others (607) (537)  
Total net deferred tax assets 322,391 315,761  
Less: valuation allowance (322,391) (315,761)  
Deferred tax assets, net of allowance  
Reconciliation of the statutory federal income tax rate to the effective tax rate      
Federal statutory tax rate (as a percent) (21.00%) (21.00%) (21.00%)
State, Net of Federal Benefit (as a percent) 2.80% 0.10% 0.10%
Valuation allowance (as a percent) 27.50% 24.40% 21.70%
Stock compensation (as a percent) 5.60% 4.70% 2.80%
Orphan drug and research and development credits (as a percent) (14.00%) (12.70%) (5.10%)
Other, net (as a percent) 2.70% 4.60% 1.50%
Effective tax rate (as a percent) 3.60% 0.10% 0.00%